Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Vortioxetine Filed in Japan for MDD: Takeda/Lundbeck
October 1, 2018
- Hisamitsu Files Transdermal Parkinson’s Disease Drug in Japan
October 1, 2018
- 2 Camps of Biosimilar Makers Seek Japan Approval for Nesp Follow-Ons
October 1, 2018
- Takeda Touts Progress in R&D Makeover, Departure from Small Molecules
September 28, 2018
- Kyorin, Teijin Dissolve Capital Alliance
September 28, 2018
- Alnylam Plants Flag in Japan Soil, Eyes 4 RNAi Therapeutic Launches in 5 Years
September 28, 2018
- Number of Sales Reps in 43 Pharmas Dwindles by 4,906 in 4 Years: Survey
September 28, 2018
- Daiichi Sankyo Begins PIII Breast Cancer Trials for DS-8201
September 27, 2018
- IBM Japan Joins Takeda’s Shonan iPark
September 27, 2018
- Celgene Seeks Japan OK for Pomalyst Triplet for MM
September 27, 2018
- Alunbrig Outstrips Xalkori in Front-Line ALK NSCLC, Cuts Disease Progression or Death Risks by 51%: Takeda
September 27, 2018
- I/O in Lung Cancer - 6: Analyst Says US Merck Claimed Victory in 2018 ASCO Confab, Applauds Trial Designs for Keytruda
September 26, 2018
- Takeda’s Brigatinib Snags European Panel OK for 2nd Line ALK-Positive NSCLC
September 26, 2018
- Xtandi Gets CHMP Backing for Additional CRPC Indication
September 26, 2018
- DS-8201 Shows Positive PI Study Data for NSCLC: Daiichi Sankyo
September 26, 2018
- European Panel Backs Approval of Kyowa Kirin’s Mogamulizumab for Mycosis Fungoides, Sézary Syndrome
September 26, 2018
- Santen Files for Japan Approval of Anti-Allergy Eye Drop
September 26, 2018
- Daiichi Sankyo, Pfizer Grab Japan Approval for Herceptin Biosimilars
September 25, 2018
- AMED Backs Project for Development of Familial Adenomatous Polyposis Therapy Applied by FunPep, 3 Universities
September 25, 2018
- Fujifilm Kyowa Kirin, Mylan Bag EU Approval of Humira Biosimilar
September 25, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…